Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.

JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

A patient's grey hair regained color during treatment with adalimumab.

Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

Sunlight exposure improved a patient's skin condition, and there may be a link between a certain disease and skin growths; a leukemia treatment caused changes in hair color and growth.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

A woman experienced hair loss, nail changes, bone marrow suppression, and low blood protein after taking azathioprine.

Epristeride's metabolism in zebrafish helps improve doping detection methods.

Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.

Axitinib treatment turned a man's grey hair back to black.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

Trilostane treatment led to full hair regrowth in most Pomeranians and all miniature poodles with alopecia X.

New treatments for lupus show promise, but more research is needed, especially for children.

TAT-GILZ peptide promotes hair growth by boosting stem cell activity.